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Surgical Residents Make Significant Contributions to Ongoing Cancer Research

The Department of Surgery’s research efforts have expanded greatly in recent years as evidenced by the
breadth and depth of resident research projects.
Dr. L. Andrew Shirley spent two years in the laboratory and was the Principal Investigator of a study
analyzing the role of the Dachshund (DACH1) cell fate determination pathway in various cancer types,
including breast, prostate, colorectal, and pancreatic cancers. The study, funded by a Radiation Therapy
Oncology Group Translational Research Program seed grant, was conducted under the mentorship of
Richard Pestell, MD, PhD, Director of the Kimmel Cancer Center. Dr. Shirley presented the findings at the
3rd Annual Academic Surgical Congress and in four peer-reviewed articles.
Jonathan Brody, PhD, a specialist in pancreatic cancer research has mentored several residents in his
laboratory. Dr. Shayna Showalter explored targets in pancreatic cancer to develop novel therapeutic
strategies and examined the effect of naturally occurring Vitamin K on pancreatic cancer cells. She found
that Vitamin K actually inhibits pancreatic cancer cell growth. Dr. Showalter also used novel nanoparticle
technology to deliver diphtheria toxin specifically to pancreatic cancer cells, therefore killing the cancer
cells without effecting the growth of normal, noncancer cells. To date, she has presented the findings at
three meetings, including the American Association for Cancer Research Annual Meeting, and in three
peer-reviewed articles.
Also under Dr. Brody’s mentorship, Dr. Timothy Williams investigated the tumor suppressor protein pp32
and its role in pancreatic tumor development. The research established that pp32 is low or absent in
poorly differentiated pancreatic cancer, it suppresses tumor growth when its expression is restored, and
impacts the response of cancer cells to certain chemotherapy drugs commonly used to treat pancreatic
cancer. To date, Dr. Williams has published three peerreviewed publications on this research, presented
posters at three meetings and shares the Award for Best Research Presentation in the Department of

Surgery.
Dr. Nikolai Bildzukewicz is continuing the work established by Dr. Williams on the role of pp32 in a drug
resistance pathway. However, his primary research focuses on Poly(ADP Ribose) Polymerase- 1 (PARP-1),
an enzyme found within the cell nucleus that serves many cellular functions including repair of damaged
DNA. In collaboration with John Pascal, PhD, Assistant Professor of Biochemistry and Molecular Biology,
Dr. Bildzukewicz is working with both normal and mutant forms of the enzyme in pancreatic cancer cells.
His findings include the concept of using novel agents, PARP-inhibitors, to sensitize pancreatic cancer
cells to platinum-based FDA-approved drugs. This work provides the proof-of-principle data for a
proposed clinical trial. Dr. Bildzukewicz presented the initial findings to the Philadelphia Academy of
Surgery meeting in February 2008.
In Dr. Susan Lanza-Jacoby’s laboratory, Dr. Matthew Rosen is studying the effect of Nexrutine, a natural
Cox-2 inhibitor on pancreatic cancer cells, and the relationship of sirtuin (a protein involved in improving
health during calorie restriction) to pancreatic cancer. Dr. Rosen has already presented findings at two
meetings including the American Association of Cancer Research. Dr. Rosen is also the recipient of the
Arnold P. Gold Foundation Humanism and Excellence in Teaching Award.
In Dr. Hwyda Arafat’s laboratory, Dr. Jennifer Sullivan is analyzing how nictotine exposure contributes to
the aggressive nature of pancreatic cancer. Her research focuses on the expression of a protein,
Osteopontin-C, which appears to be increased in patients with pancreatic cancer, especially those with a
history of smoking. This protein could be a potential target for future therapy.
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Clinical Integration

Overview

Charles J. Yeo, MD
Samuel D. Gross Professor and
Chair, Department of Surgery

The Spring of 2009 represents an exciting
time here in the Department of Surgery.
Despite the turbulent economic times,
our clinical footprint has grown nicely,
averaging a 5 to 12% increase per year for
the last three years. Newer programs such
as our minimally invasive esophagectomy
and pancreatectomy programs, our
bariatric surgery program, our mechanical
heart support program, and our thriving
acute care surgery (and intensivist)
program are examples of success stories.
We have received good news on the
research front. Our residents and faculty
just completed a very busy Fall and Winter,
when well over a dozen presentations were
made at national fora, such as the Southern
Surgical, the 4th Academic Surgical
Congress, the Southeastern Surgical, and
the American Hepato-Pancreato-Biliary
Association, amongst others. Additionally,
we are delighted to have recently been
notified of major grant awards to Drs.
Lanza-Jacoby and Tulenko, representing
NIH dollars into the Department. Our clinical
research has grown nicely, and the addition
of Sharon Molotsky, RN, BSN, CCRC as our
Clinical Research Nurse Project Manager
will do much to ensure the attention to
detail needed for our clinical trials.
My thanks go out to all members of the
Department for their enthusiasm, hard
work, clinical expertise and academic
performance over the last several years.
It has been wonderful to see Jefferson’s
stature rise amongst other academic
medical centers, as we have added faculty,
increased our clinical volumes, added
new clinical programs, and raised the
research profile (both for our basic science
researchers and for our clinicians).

Residency Program graduates, Drs. Jay Jenoff and Niels Martin, have returned to Jefferson
as Assistant Professors in the Acute Care Surgery Division.

Acute Care Surgery Expands
its Faculty, Facilities & Research
New faculty, upgrades to the Intensive
Care Unit (ICU), and multiple new trials
and studies are just some of the changes
underway in the Acute Care Surgery
Division. The addition of Jay Jenoff, MD,
and Niels Martin, MD, brings the Division
team to seven faculty, strengthening its
intensivist program, which makes an
attending acute care surgeon available 24
hours a day, 7 days a week.
Drs. Jenoff and Martin recently joined
the Division after completing Fellowships in
Traumatology and Surgical Critical Care at
the Hospital of The University of
Pennsylvania. Dr. Jenoff, Assistant Professor
of Surgery and a 2005 graduate of the
Jefferson Surgery residency program, is
Board Certified in both surgery and critical
care medicine. Dr. Martin, a 2006 graduate
of Jefferson’s residency program is also
Board Certified in surgery and critical care
medicine and has been named the Associate
Program Director of Graduate Education.
As part of Jefferson’s commitment to
continually improving the care and
experience of patients, the hospital is
building a new, state-of-the-art ICU facility
in the Gibbon Building on Jefferson’s
Center City campus. Construction is
expected to be completed during this year
and will add to the existing ICU. The new
space will accommodate 34 beds, half of
which will be dedicated to surgical patients.

“This fully functional ICU will have the
most advanced technology, tools and
instruments available,” says Dr. Martin, “so
that we can respond to a patient’s needs,
from pre- and post-operative care to
bedside procedures, under ideal conditions
with the optimal equipment.”
“Like any professional team, each
member plays an important role,” says Dr.

Changing Lives Through Research
Jenoff, “and our two trauma nurse
practitioners, Alannah Ryan, CRNP, and
Catherine Gill-Preston, CRNP, are
absolutely invaluable to the doctors and
patients. Their case management skills,
skill level, and compassion for patients are
second-to-none.”
In addition to clinical priorities, the
Division is placing a renewed emphasis on
research and has recently undertaken
several clinical trials and studies. “A
number of these new studies make
Jefferson—and our Division in
particular—an exciting place to be right
now, a place to grow as a professional,”
says Dr. Martin. In trauma, for example,
the group is looking at new methods of
stabilization, prevention studies, and
resuscitation. Faculty members are also
studying abdominal wall outcomes and
developing new protocols, while working
with industry representatives on device
implementation. Research projects include
multidisciplinary collaborations with
Jefferson colleagues in rehabilitation and
orthopedics. Over the next 12–15 months
Division faculty will present findings at
multiple national academic meetings.
For more information about the Acute Care
Surgery Division, visit their new website at
www.jefferson.edu/acutecare

Please Welcome
Dr. Joshua Curtin in the
New Transplant Laboratory
Joshua Curtin, PhD, is a
research fellow in the lab
of Cataldo Doria, MD, PhD,
focusing on the regulation
of tumor cell growth and
division, primarily in the liver.
He examines how molecular
components of cellular signaling
pathways function to regulate
cell growth and cell death.
Dr. Curtin’s doctoral research studied the
actions of natural derivatives of Vitamin A
known as tumor cell differentiators. Derivatives
of Vitamin A are a class of compounds known
as retinoids, which have been shown to
prevent the unchecked division of cancer
cells. “Although traditional chemotherapies
kill both the mutated cancer cells and the
healthy normal cells,” Dr. Curtin explains,
“this treatment stops only the cancer cells
from dividing.”

Dr. Curtin has coupled his expertise as
a cancer biologist with his experience
as a post-doctoral fellow in liver biology.
“The ultimate goal,” he explains, “is to
translate discovery in the lab into improved
clinical treatment for patients suffering
from liver cancer.”
To read more about this research, go to
www.jeffersonhospital.org/transplant

On the Job
Zi-Xuan (Zoe) Wang, PhD
Zi-XuanWang, PhD, is an Assistant
Professor of Surgery, with a secondary
appointment in the Department
of Pathology, Anatomy, and Cell
Biology, where she is the Assistant
Director of the Clinical Microbiology
Laboratory. She joined Jefferson in
October 2008 after six years at the
Medical College of Georgia where
she was the Scientific Director of the
Molecular Diagnostics Laboratory.
What is the focus of your research?

Drs. Shayna Showalter, Matthew Rosen, L. Andrew Shirley, Nikolai Bildzukewicz,
Jennifer Sullivan and Timothy Williams have made impressive contributions to cancer
research at Jefferson as part of their surgical residency training.

Surgical Residents Make
Significant Contributions to
Ongoing Cancer Research
The Department of Surgery’s research
efforts have expanded greatly in recent
years as evidenced by the breadth and
depth of resident research projects.
Dr. L. Andrew Shirley spent two years
in the laboratory and was the Principal
Investigator of a study analyzing the role of
the Dachshund (DACH1) cell fate
determination pathway in various cancer
types, including breast, prostate, colorectal,
and pancreatic cancers. The study, funded
by a Radiation Therapy Oncology Group
Translational Research Program seed
grant, was conducted under the
mentorship of Richard Pestell, MD, PhD,
Director of the Kimmel Cancer Center. Dr.
Shirley presented the findings at the 3rd
Annual Academic Surgical Congress and
in four peer-reviewed articles.
Jonathan Brody, PhD, a specialist in
pancreatic cancer research has mentored
several residents in his laboratory.
Dr. Shayna Showalter explored targets
in pancreatic cancer to develop novel
therapeutic strategies and examined the
effect of naturally occurring Vitamin K on
pancreatic cancer cells. She found that

Vitamin K actually inhibits pancreatic
cancer cell growth. Dr. Showalter also used
novel nanoparticle technology to deliver
diphtheria toxin specifically to pancreatic
cancer cells, therefore killing the cancer
cells without effecting the growth of
normal, noncancer cells. To date, she has
presented the findings at three meetings,
including the American Association for
Cancer Research Annual Meeting, and in
three peer-reviewed articles.
Also under Dr. Brody’s mentorship,
Dr. Timothy Williams investigated the
tumor suppressor protein pp32 and its role
in pancreatic tumor development. The
research established that pp32 is low or
absent in poorly differentiated pancreatic
cancer, it suppresses tumor growth when
its expression is restored, and impacts the
response of cancer cells to certain
chemotherapy drugs commonly used to
treat pancreatic cancer. To date, Dr.
Williams has published three peerreviewed publications on this research,
presented posters at three meetings and
shares the Award for Best Research
Presentation in the Department of Surgery.
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My passion is personalized medicine:
to find out how and why certain
therapies/medicines do or do
not work and then to develop a
customized approach to enhance a
patient’s treatment. Since people can
metabolize or respond to medicines
in various ways, genetic analysis can
predict a certain patient’s response, so
that therapeutics can be administered
and dosed optimally.
How do you use technology in
your work?

DNA sequencing and gene chips
have made testing individuals feasible.
We characterize specific aspects of
cancer and host genomes to predict
whether a drug will be effective
or whether serious side effects
Dr. Nikolai Bildzukewicz is continuing
the work established by Dr. Williams on
the role of pp32 in a drug resistance
pathway. However, his primary research
focuses on Poly(ADP Ribose) Polymerase1 (PARP-1), an enzyme found within the
cell nucleus that serves many cellular
functions including repair of damaged
DNA. In collaboration with John Pascal,
PhD, Assistant Professor of Biochemistry
and Molecular Biology, Dr. Bildzukewicz
is working with both normal and mutant
forms of the enzyme in pancreatic cancer
cells. His findings include the concept of
using novel agents, PARP-inhibitors, to
sensitize pancreatic cancer cells to
platinum-based FDA-approved drugs.
This work provides the proof-of-principle
data for a proposed clinical trial. Dr.
Bildzukewicz presented the initial findings
to the Philadelphia Academy of Surgery
meeting in February 2008.
In Dr. Susan Lanza-Jacoby’s laboratory,
Dr. Matthew Rosen is studying the effect
of Nexrutine, a natural Cox-2 inhibitor on

will emerge. Characterization of
mutations in the patient’s genome can
predict drug resistance and provide a
personalized approach.
What motivates you on a day-today basis?

As a scientist, I am dedicated to
improving the health of human
beings and I especially enjoy working
with the surgical faculty on pancreatic
cancer and translational research.
As a team, our analytical skills and
emerging technologies have pushed
us to the leading edge of diagnostics.
Future collaborations with other
Jefferson researchers will further
advance our progress and ultimately
improve medicine.

pancreatic cancer cells, and the
relationship of sirtuin (a protein involved
in improving health during calorie
restriction) to pancreatic cancer. Dr.
Rosen has already presented findings at
two meetings including the American
Association of Cancer Research. Dr.
Rosen is also the recipient of the Arnold
P. Gold Foundation Humanism and
Excellence in Teaching Award.
In Dr. Hwyda Arafat’s laboratory,
Dr. Jennifer Sullivan is analyzing how
nictotine exposure contributes to the
aggressive nature of pancreatic cancer.
Her research focuses on the expression of
a protein, Osteopontin-C, which appears
to be increased in patients with pancreatic
cancer, especially those with a history of
smoking. This protein could be a potential
target for future therapy. Dr. Sullivan
recently presented her data at the
Academic Surgical Congress and a
manuscript has been accepted for
publication in Surgery.
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